Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADVM Adverum Biotechnologies	$3.08 +1.7%	$2.59	$1.78 ▼ $8.56	$64.62M	0.77	239,280 shs	65,631 shs
ALGS Aligos Therapeutics	$10.55 -4.6%	$8.41	$3.76 ▼ $46.80	$64.89M	2.77	167,717 shs	61,168 shs
CUE Cue Biopharma	$0.78 -2.7%	$0.79	$0.45 ▼ $1.99	$59.96M	1.53	253,672 shs	82,041 shs
CYAD Celyad	$0.60	$0.67	$0.46 ▼ $3.07	$15.91M	N/A	N/A	3,009 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADVM Adverum Biotechnologies	-0.33%	+3.41%	+22.67%	+37.10%	-56.21%
ALGS Aligos Therapeutics	-2.38%	+12.40%	+37.56%	+105.19%	-15.25%
CUE Cue Biopharma	-3.43%	-1.22%	-2.29%	+21.04%	+14.50%
CYAD Celyad	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADVM Adverum Biotechnologies	4.1306 of 5 stars	3.4	3.0	0.0	4.8	3.8	0.8	0.0
ALGS Aligos Therapeutics	4.425 of 5 stars	3.5	4.0	0.0	4.8	2.4	1.7	0.6
CUE Cue Biopharma	2.6011 of 5 stars	0.0	5.0	0.0	4.7	3.0	0.8	0.6
CYAD Celyad	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADVM Adverum Biotechnologies	2.75	Moderate Buy	$19.75	541.23% Upside
ALGS Aligos Therapeutics	3.00	Buy	$50.00	373.93% Upside
CUE Cue Biopharma	0.00	N/A	N/A	N/A
CYAD Celyad	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CYAD, ADVM, CUE, and ALGS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ALGS Aligos Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
8/13/2025	ADVM Adverum Biotechnologies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00
6/26/2025	ADVM Adverum Biotechnologies	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $12.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADVM Adverum Biotechnologies	$1M	64.62	N/A	N/A	($0.96) per share	-3.21
ALGS Aligos Therapeutics	$3.17M	20.45	N/A	N/A	$16.56 per share	0.64
CUE Cue Biopharma	$9.29M	6.45	N/A	N/A	$0.24 per share	3.25
CYAD Celyad	$200K	79.56	N/A	N/A	$0.02 per share	30.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADVM Adverum Biotechnologies	-$130.93M	-$7.85	N/A	N/A	N/A	N/A	-297.29%	-101.40%	11/3/2025 (Estimated)
ALGS Aligos Therapeutics	-$131.21M	-$19.79	N/A	N/A	N/A	-2,337.24%	-22.41%	-12.09%	11/5/2025 (Estimated)
CUE Cue Biopharma	-$40.67M	-$0.56	N/A	N/A	N/A	-469.35%	-230.13%	-111.16%	11/13/2025 (Estimated)
CYAD Celyad	-$6.30M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest CYAD, ADVM, CUE, and ALGS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ADVM Adverum Biotechnologies	-$2.24	-$2.34	-$0.10	-$2.34	N/A	N/A
8/12/2025	Q2 2025	CUE Cue Biopharma	-$0.13	-$0.09	+$0.04	-$0.09	$2.00 million	$2.95 million
8/6/2025	Q2 2025	ALGS Aligos Therapeutics	-$2.35	-$1.53	+$0.82	-$1.53	$0.43 million	$0.97 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADVM Adverum Biotechnologies	N/A	N/A	N/A	N/A	N/A
ALGS Aligos Therapeutics	N/A	N/A	N/A	N/A	N/A
CUE Cue Biopharma	N/A	N/A	N/A	N/A	N/A
CYAD Celyad	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADVM Adverum Biotechnologies	N/A	1.54	1.54
ALGS Aligos Therapeutics	N/A	6.31	6.31
CUE Cue Biopharma	0.01	1.60	1.60
CYAD Celyad	1.49	2.29	2.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADVM Adverum Biotechnologies	48.17%
ALGS Aligos Therapeutics	60.43%
CUE Cue Biopharma	35.04%
CYAD Celyad	N/A

Insider Ownership

Company	Insider Ownership
ADVM Adverum Biotechnologies	6.00%
ALGS Aligos Therapeutics	4.80%
CUE Cue Biopharma	10.78%
CYAD Celyad	0.94%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADVM Adverum Biotechnologies	190	20.98 million	19.73 million	Optionable
ALGS Aligos Therapeutics	90	6.15 million	5.86 million	No Data
CUE Cue Biopharma	60	76.85 million	68.56 million	Optionable
CYAD Celyad	95	26.52 million	26.28 million	Not Optionable

CYAD, ADVM, CUE, and ALGS Headlines

Recent News About These Companies

Étranglée financièrement, la biotech belge Celyad Oncology arrête ses activités de recherche développement

August 26 at 6:37 AM | lalibre.beL

Étranglée financièrement, Celyad Oncology arrête ses activités de recherche-développement

August 26 at 6:37 AM | dhnet.beD

Celyad Oncology annonce la cessation des activités R&D

August 26 at 6:37 AM | fr.finance.yahoo.com

Celyad Oncology Announces Discontinuation of R&D Activities

August 26 at 6:37 AM | finance.yahoo.com

Celyad Oncology Announces €1 Million Private Placement

July 28, 2025 | finance.yahoo.com

Celyad Oncology annonce une revue stratégique approfondie

June 25, 2025 | zonebourse.comZ

Celyad Oncology lance une revue stratégique face à une trésorerie limitée

June 25, 2025 | zonebourse.comZ

La biotech Celyad évalue plusieurs pistes pour survivre

June 24, 2025 | msn.com

Celyad Oncology annonce une revue de sa stratégie d’entreprise

June 24, 2025 | fr.finance.yahoo.com

Celyad Oncology Announces Strategic Review

June 24, 2025 | finance.yahoo.com

Celyad Oncology SA GAAP EPS of -€0.14, revenue of €0.2M

April 2, 2025 | seekingalpha.com

Natural killer cells 'a hundred times cheaper' than CAR-T

March 7, 2025 | pharmaphorum.comP

Celyad Oncology to Present at the 2024 SITC Annual Meeting

October 7, 2024 | finance.yahoo.com

Celyad Oncology Announces Appointment of Matt Kane as Chief Executive Officer

September 16, 2024 | finance.yahoo.com

Celyad Oncology Reports First Half Year 2024 Financial Results and Recent Business Highlights

September 13, 2024 | finance.yahoo.com

Celyad Oncology SA (CYADB.XC)

July 19, 2024 | finance.yahoo.com

Celyad Oncology Reports Full Year 2023 Financial Results and Recent Business Highlights

April 4, 2024 | finance.yahoo.com

CSBR Champions Oncology, Inc.

March 29, 2024 | seekingalpha.com

News - Celyad Oncology

February 13, 2024 | thepharmaletter.comT

Celyad Oncology SA: Celyad Oncology provides fourth quarter 2023 business update and 2024 outlook

January 17, 2024 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYAD, ADVM, CUE, and ALGS Company Descriptions

Adverum Biotechnologies NASDAQ:ADVM

$3.08 +0.05 (+1.65%)

Closing price 04:00 PM Eastern

Extended Trading

$3.08 0.00 (-0.16%)

As of 04:10 PM Eastern

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Aligos Therapeutics NASDAQ:ALGS

$10.55 -0.51 (-4.61%)

Closing price 04:00 PM Eastern

Extended Trading

$10.58 +0.04 (+0.33%)

As of 04:52 PM Eastern

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Cue Biopharma NASDAQ:CUE

$0.78 -0.02 (-2.66%)

Closing price 04:00 PM Eastern

Extended Trading

$0.80 +0.02 (+2.92%)

As of 04:28 PM Eastern

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Celyad NASDAQ:CYAD

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time